Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anxiety
Biotech
Neuphoria nixes social anxiety program after phase 3 flop
Neuphoria’s stock has plummeted 67% after the announcement, dropping from Monday’s close of $15.40 per share to $5 as of 10 a.m. ET today.
Gabrielle Masson
Oct 21, 2025 10:44am
Seaport loads $225M for Karuna vets' voyage to milestones
Oct 21, 2024 8:05am
Karuna's captains set sail in new neuropsychiatric biotech
Apr 9, 2024 8:25am
Neuropsych biotech Engrail closes $157M series B
Mar 19, 2024 8:00am
FDA accepts first AI algorithm to drug development tool pilot
Jan 26, 2024 1:35pm
MindMed links LSD to reduced anxiety in phase 2b, plots phase 3
Dec 14, 2023 9:32am
